Mutant NGAL proteins and uses thereof
AssigneeThe Trustees of Columbia University in the City of New York
InventorsJonathan Barasch, Andong Qiu
Life of this patent
Estimating the term…
Abstract
In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
Claims20
A method of treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising:
- (i) a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 2;
- (ii) a polypeptide that comprises SEQ ID NO:
- 2;
- (iii) a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 252, wherein the polypeptide does not comprise a cysteine at amino acid 87 of SEQ ID NO:
- 252;
- or
- (iv) a polypeptide that comprises SEQ ID NO:
- 252.
Dependencies are inferred from the claim text.